(20) Each group included 7 postmenopausal women, with 18 total women assigned to the liraglutide group and 19 to the control group
The Role of GLP-1 in Longevity: Optimizing Health through Nutrition, Fitness, and Mindfulness In the quest for a healthier, longer life, scientists and fitness experts have been paying increasing attention to how our bodies regulate hunger, blood sugar, and energy balance
The semaglutide and tirzepatide trials changed that expectation: Semaglutide 2.4 mg once weekly produced average weight loss around 15% at ~68 weeks in adults without diabetes, with a substantial fraction of participants losing 1520% of baseline weight
Results showed that among people without diabetes, GLP-1 drug use rose from 0.1% of the population in 2018 to 0.4% in 2022
This randomized, double-blind trial enrolled adults with obesity or those who were overweight with at least one related health condition